GTBP
****Sponsored by TD Media, LLC on Behalf of GT Biopharma
GT Biopharma Doses First Patient in GTB-5550 — The Platform Just Got a Whole Lot More Interesting
The TriKE® platform is modular, scalable, and already validated in human patients
The TriKE® platform is not speculative — it has already demonstrated clinical proof of concept
READ THE INVESTOR PRESENTATION HERE
***BREAKING THIS MORNING
GT Biopharma Reports First Quarter 2026 Financial Results
PUBLISHED
MAY 15, 2026 8:00AM EDT
Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with additional updates anticipated in 2H 2026
Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 initiated May 2026 with updates anticipated in 2H 2026 as enrollment progresses through dose escalation cohorts
Cash balance as of March 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026
SAN FRANCISCO, CALIFORNIA, May 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced first quarter 2026 financial results for the period ended March 31, 2026.
"With the initiation of our GTB-5550 Phase 1 trial, we have now advanced three TriKE® candidates into the clinic, a significant milestone that underscores the continued momentum of our pipeline," said Michael Breen, Executive Chairman and Chief Executive Officer. "GTB-3650 has demonstrated an excellent safety profile thus far, and we look forward to continuing enrollment progress. With sufficient cash runway through Q4 2026, we look forward to providing updates on both programs in the second half of 2026."
GTB-3650 TriKE for CD33 positive leukemias
The ongoing Phase 1 dose escalation study is evaluating GTB-3650 for relapsed or refractory (r/r) CD33 expressing hematologic malignancies, including refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Enrollment is ongoing, with Cohort 4 enrollment now complete and a total of 8 patients treated across the first four cohorts; the Company expects to provide continued progress updates throughout 2026. Dose escalation may continue up to Cohort 7 as necessary with the potential to evaluate GTB-3650 in a total of 14 patients (two patients per cohort). GTB-3650 is dosed in two-week blocks, two weeks on and two weeks off, for up to four months based on clinical benefit. The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, in vivo expansion of endogenous patient NK cells and clinical activity.
GTB-5550 TriKE for B7H3 positive solid tumor cancers
The ongoing Phase 1 trial with GTB-5550 is the first nanobody TriKE® tested with more patient-friendly subcutaneous dosing. The Phase 1a dose escalation portion of the trial is focused primarily on enrolling prostate cancer patients and will evaluate up to 6 dose levels to identify the maximum tolerated dose (MTD). After the dose escalation phase, the Phase 1b expansion component will enroll patients with up to 7 different tumor types (castration-resistant prostate cancer, ovarian cancer, breast cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer) and further evaluate its safety, tolerability and preliminary anti-tumor activity.
GTB-5550 will be administered by subcutaneous (SQ) injection in the abdominal area for 5 consecutive days during Week 1 and Week 2 followed by 2 weeks of no treatment. One treatment cycle is 4 weeks in duration. Subsequent cycles receive treatment three times weekly for 2 weeks followed by 2 weeks of no treatment. A minimum of 2 cycles is planned, and patient-appropriate disease reassessment is performed after 2 cycles and every 8-12 weeks thereafter. Treatment may continue until disease progression, unacceptable toxicity, patient refusal, or treatment is no longer in the best interest of the patient. Patients are followed for 12 months to determine progression free survival (PFS) and overall survival (OS). More details can be found on clinicaltrials.gov with the identifier: NCT07541573.
First Quarter Ended March 31, 2026 Financial Summary
Cash Position: The Company had cash and cash equivalents of approximately $9 millionas of March 31, 2026, which is anticipated to be sufficient to fund the Company’s operations through the fourth quarter of 2026.
Research and Development (R&D) Expenses: R&D expenses for the second quarter of 2026 were approximately $400,000 compared to $1.1 million for the same comparable quarter of 2025. The $700,000 decrease was primarily due to a reduction in production costs. R&D expenses primarily relate to the Company’s continued licensing, development, production, and clinical trials of its most advanced TriKE® product candidates GTB-3650 and GTB-5550 along with the progression on other promising product candidates.
Selling, General and Administrative (SG&A) Expenses (Excluding Stock Compensation): SG&A expenses for the second quarter of 2026 were approximately $2.4 millioncompared to $800,000 for the same comparable quarter of 2025. The $1.6 millionincrease was primarily due to an increase in marketing expenses, and to a lesser extent, legal fees.
Loss from Operations: The Company reported a loss from operations for the second quarter of 2026 of approximately $2.8 million compared to $1.9 million for the same comparable quarter of 2025. The 900,000 increase was primarily due to $1.6 millionincrease in SG&A (as described above).
Net Loss: The Company reported a net loss of approximately $2.8 million for the second quarter of 2026, compared to $800,000 for same comparable quarter of 2025. The $2 million increase consisted primarily of a $1.6 million increase in SG&A (as described above), and a decrease in non-recurring other income of approximately $1.1 million.
_________________________________
Hello Everyone,
After two huge bottom bouncers in a row we are changing pace and putting a major momentum. Like our last one this just hit it's 52 week low and has exploded since.
GT Biopharma is a San Francisco-based clinical-stage biopharmaceutical company developing next-generation immuno-oncology therapeutics built around its proprietary TriKE® (Tri-Specific NK Cell Engager) platform. Unlike CAR-T therapies, which require harvesting and modifying a patient's cells outside the body, the TriKE® approach is designed to activate and enhance a patient's own natural killer (NK) cells directly in vivo — a potentially safer, more scalable, and more commercially attractive approach to cancer immunotherapy.
The company holds an exclusive worldwide license with the University of Minnesota to develop and commercialize the TriKE® technology. The platform is built around a tri-specific molecule with three functional domains: an anti-CD16 nanobody that binds and activates NK cells, an IL-15 crosslinker that promotes NK cell expansion and persistence at the tumor site, and an anti-tumor binding domain that directs those NK cells to specific cancer markers. This modular design allows GT Biopharma to efficiently adapt the platform across multiple tumor targets — a meaningful structural advantage.
The Pipeline
GT Biopharma currently has three named TriKE® candidates in various stages of development:
GTB-3650 is the company's lead clinical asset — a second-generation camelid nanobody TriKE® currently in a Phase 1 dose escalation trial for relapsed or refractory CD33-expressing hematologic malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Cohort 5 dosing is expected to begin in Q2 2026, with a data update anticipated in Q3 2026.
GTB-5550 is a B7-H3-targeted TriKE® that received FDA IND clearance in February 2026, with a Phase 1 basket trial planned for mid-2026 covering up to seven metastatic solid tumor types, including prostate, ovarian, breast, lung, pancreatic, head and neck, and bladder cancers.
GTB-7550 is a CD19-targeted preclinical candidate being developed for lupus and other autoimmune disorders, representing a potential expansion of the platform well beyond oncology.
Proof of Concept Already Established
The TriKE® platform is not speculative — it has already demonstrated clinical proof of concept. GT Biopharma's first-generation candidate, GTB-3550, completed a Phase 1 study in AML and MDS patients and showed reproducible NK cell proliferation, activation, and persistence across all patients and all dose levels, with minimal clinically significant toxicity. In select patients, the therapy produced meaningful reductions in CD33+ bone marrow blast levels, ranging from 33% to nearly 64% — encouraging signals for a first-in-class modality at early dose levels.
The second-generation GTB-3650 builds on those results with improved potency, enhanced binding affinity through camelid nanobody technology, and full proprietary ownership by GT Biopharma — positioning the company to capture the full commercial value of any future success.
Market Opportunity
The cancer immunotherapy market was valued at approximately $136 billion in 2025 and is projected to reach $367 billion by 2035. Within that landscape, the NK cell therapeutics segment is growing even faster, expected to expand from $3.2 billion in 2024 to $8.6 billion by 2033. Large pharmaceutical companies have already taken notice — Sanofi and Gilead each completed NK cell engager deals valued at over $1 billion in upfront and milestone payments, validating the commercial potential of this modality at the highest levels of the industry.
Financial Position
As of early 2026, GT Biopharma held approximately $9 million in cash, with management guiding for a funded runway through Q4 2026 — covering both continued enrollment in the GTB-3650 trial and the planned initiation of the GTB-5550 basket study. Full year 2025 R&D expenses came in at approximately $3.5 million, reflecting a disciplined approach to capital allocation as the company sharpens its development focus.
With a market cap below $12 million, two active or imminent clinical programs, a Q3 2026 data catalyst on the horizon, and a platform designed for expansion across oncology and autoimmune disease, GT Biopharma represents a high-risk, high-potential setup that is difficult to ignore for investors watching the NK cell engager space closely.
GT Biopharma Doses First Patient in GTB-5550 — The Platform Just Got a Whole Lot More Interesting
GT Biopharma crossed a major threshold yesterday, announcing that the first patient has been dosed in its Phase 1 clinical trial evaluating GTB-5550, its B7-H3-targeted NK cell engager for solid tumors. For a company with a market cap still sitting below $12 million, this is the kind of catalyst that tends to get overlooked until it isn't — and investors paying attention now may be glad they did. GT Biopharma is no longer a one-trial story. With GTB-3650 actively enrolling in blood cancers and GTB-5550 now in the clinic targeting solid tumors, the company has quietly become a two-trial clinical-stage biopharmaceutical company operating on two of the most important fronts in cancer immunotherapy.
What makes GTB-5550 particularly compelling is the target. B7-H3 is broadly expressed across many of the most common and difficult-to-treat solid tumor cancers, and in metastatic castration-resistant prostate cancer specifically, it is present in over 90% of tumors. That is not a niche indication — that is a massive addressable patient population, and the company is going after it with a platform that has already demonstrated proof of concept in human patients. Equally important is the dosing innovation: GTB-5550 will be administered via subcutaneous injection rather than intravenously, making it more patient-friendly and potentially far more practical from a commercial standpoint down the road.
The trial itself is well structured. The Phase 1a dose escalation phase starts with prostate cancer patients and works through up to six dose levels to identify the maximum tolerated dose, with PSA serving as an early biomarker of activity — meaning the market could start seeing meaningful signals relatively quickly. From there, the Phase 1b expansion phase broadens to up to seven solid tumor types including ovarian, breast, lung, pancreatic, head and neck, and bladder cancers. Patients will be followed for 12 months tracking progression-free survival and overall survival, and the company has committed to providing updates throughout the second half of 2026.
The bottom line is straightforward. GT Biopharma now has two active clinical programs, a funded runway into Q4 2026, a Q3 data update coming on GTB-3650, and a freshly initiated trial in solid tumors that covers some of the largest cancer markets in the world. The TriKE® platform is modular, scalable, and already validated in human patients. For investors who follow early-stage biotech, this is exactly the kind of setup worth watching closely — a platform with real science behind it, multiple near-term catalysts ahead, and a valuation that has not yet caught up to the story.
GTB-3650 TriKE®
GTB-3650 is the company's first 2nd generation camelid nanobody TriKE® being tested clinically for the treatment of CD33 positive leukemias, including AML and MDS. GTB-3650 TriKE is the first TriKE clinical product that utilizes camelid nanobody technology. GTB-3650 TriKE is a Tri-specific Killer Engager molecule composed of a camelid nanobody that binds the CD16 receptor on NK cells, a single chain variable fragment (scFv) that recognizes CD33 on tumor cells, and human wild type IL-15. The IND application was cleared and enrollment started January 21, 2025. The ongoing Phase 1 dose escalation study is evaluating GTB-3650 for relapsed or refractory (r/r) CD33 expressing hematologic malignancies, including refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Enrollment in Cohort 4 (10 µg/kg/day) is ongoing, and the Company expects to initiate dosing in Cohort 5 (25 µg/kg/day) in Q2 2026. The Company anticipates providing the next update in the third quarter of 2026, which would include longer term follow-up on the six patients in Cohort 1 through 3 as well as initial observations from patients in Cohort 4 and Cohort 5. Dose escalation may continue up to Cohort 7 as necessary with the potential to evaluate GTB-3650 in a total of 14 patients (two patients per cohort). GTB-3650 is dosed in two-week blocks, two weeks on and two weeks off, for up to four months based on clinical benefit. The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, in vivo expansion of endogenous patient NK cells and clinical activity. More details can be found on clinicaltrials.gov with the identifier: NCT06594445.
GTB-5550 TriKE®
GTB-5550 is a camelid (cam) anti-CD16/WT IL-15/cam anti-B7-H3 tri-specific natural killer (TriKE) cell engager, with a single chain recombinant TriKE® comprised of three components joined by flexible linkers: 1) a nanobody arm that engages the CD16 activating receptor (camelid anti-CD16) on natural killer (NK) cells; 2) a wildtype IL-15 (WT IL-15) linker arm to drive NK cell proliferation, priming, and survival; and 3) a nanobody arm that specifically engages B7-H3 (camelid anti-B7-H3) to target the antigen expressed on tumor cells.
The Phase 1 basket trial with GTB-5550 will be the first dual nanobody TriKE® tested with more patient-friendly subcutaneous dosing. The Phase 1a dose escalation portion of the trial will test up to 6 dose levels to identify the maximum tolerated dose (MTD). After the dose escalation phase, the Phase 2 expansion component of the trial will then confirm the MTD identified in the Phase 1a trial in up to seven different possible metastatic disease cohorts (castration-resistant prostate cancer, ovarian cancer, breast cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer) and further evaluate its safety, tolerability and preliminary anti-tumor activity. The Company remains well on track to initiate the trial in mid-2026.
GTB-5550 will be administered by subcutaneous (SQ) injection in the abdominal area for 5 consecutive days during Week 1 and Week 2 followed by 2 weeks of no treatment. One treatment cycle is 4 weeks in duration. A minimum of 2 cycles is planned, and patient-appropriate disease reassessment is performed after 2 cycles and every 8-12 weeks thereafter. Treatment may continue until disease progression, unacceptable toxicity, patient refusal, or treatment is no longer in the best interest of the patient. Patients are followed for 12 months to determine progression free survival (PFS) and overall survival (OS).
GTB-7550 TriKE®
The GTB-7550 TriKE product candidate is in development for the treatment of CD19 positive lymphoid malignancies and autoimmune disease. GTB-7550 TriKE is a tri-specific molecule composed of a camelid nanobody that binds the CD16 receptor on NK cells, the single chain variable fragment (scFv) of an anti-CD19 antibody, and human wild type IL-15. GTB-7550 TriKE has been tested and published pre-clinically using models of lymphoma and chronic lymphocytic leukemia. Based on its early preclinical activity targeting normal B-cells, studies are ongoing to develop GTB-7550 in autoimmune disease.
GTB-3550 TriKE® (Supplanted by Second Generation GTB-3650)
GTB-3550 was the company's 1st clinical trial using a 1st generation TriKE product candidate that was initially evaluated in a Phase 1 clinical trial for the treatment of relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and human mutant IL-15. In the completed Phase 1 clinical study, GTB-3550 was shown to be safe and well-tolerated. The study of GTB-3550 demonstrated clinical proof of concept of in vivo activity. GTB-3550 and the 1st generation platform was discontinued after strong data suggested that the 2nd generation TriKE was more potent and exhibited better preclinical anti-tumor activity with camelid nanobody technology and wild type IL-15.
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
Published
May 14, 2026 9:15am EDT
Issued on behalf of GT Biopharma, Inc.
From bispecific ADCs at IDEAYA to a GSK partnership at Summit, B7-H3 has become one of the most actively pursued antigens in solid tumor oncology — and a new natural killer cell engager just entered the clinic
SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could quite figure out how to hit. The protein is broadly overexpressed across some of the most common — and most lethal — solid tumors, including prostate, lung, breast, ovarian, head and neck, and pancreatic cancers. It is largely absent from healthy tissue. It correlates with poor prognosis. On paper, it has every quality a drug developer wants. In practice, three B7-H3-targeting antibody-drug conjugates have entered the clinic, and none have yet been approved [1].
That is starting to change.
In the first half of 2026, a wave of new B7-H3-directed programs from across the U.S. oncology landscape has reached early clinical milestones, ranging from bispecific antibody-drug conjugates to systemic radiopharmaceuticals to natural killer cell engagers. The mechanisms vary widely. The target does not.
GT Biopharma, Inc. (NASDAQ: GTBP) added itself to that list this week, announcing that the first patient has been dosed in a Phase 1 dose-escalation basket trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager for solid tumors expressing B7-H3 [2]. GTB-5550 is the third TriKE® (Tri-specific Killer Engager) molecule from GT Biopharma to enter the clinic and the first to be tested with subcutaneous dosing — a notable design choice in a category where most engager therapies have historically required continuous infusion. The dose-escalation phase will focus primarily on prostate cancer, where, according to Dr. Nicholas Zorko of the University of Minnesota, B7-H3 is expressed in over 90% of metastatic castration-resistant tumors and PSA can serve as an early biomarker of therapeutic activity [2].
"Dosing the first patient in our GTB-5550 Phase 1 trial is a pivotal milestone for GT Biopharma and represents the natural evolution of our TriKE® platform into the broader opportunity of treating patients with a variety of solid tumors," said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, in the company's announcement [2]. After dose escalation, the Phase 1b expansion will enroll patients across up to seven distinct tumor types: castration-resistant prostate, ovarian, breast, head and neck, non-small cell lung, pancreatic, and bladder cancer.
Step back from the molecule, though, and the more striking story is the company GT Biopharma now finds itself in.
Big Pharma Buys In: Summit Therapeutics × GSK
Just four months earlier, Summit Therapeutics Inc. (NASDAQ: SMMT) — currently one of the largest publicly traded oncology biotechs by market capitalization, with a market value around $14 billion as of early 2026 [3] — announced a clinical trial collaboration with GSK plc to evaluate Summit's lead bispecific antibody ivonescimab in combination with GSK's novel investigational B7-H3-targeting antibody-drug conjugate, risvutatug rezetecan (also known as GSK'227), across multiple solid tumor settings, including small cell lung cancer [4].
Risvutatug rezetecan is itself a high-profile asset: GSK acquired exclusive worldwide rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma, and GSK's global Phase 3 trial for the drug in relapsed extensive-stage small cell lung cancer began in August 2025 [4]. The combination study with Summit is expected to begin dosing patients in mid-2026.
The takeaway for investors watching the antigen is that B7-H3 is no longer an academic curiosity. It is at the center of a deal between one of the most-watched names in U.S. oncology biotech and one of the world's largest pharmaceutical companies.
Precision Oncology Gets Bispecific
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, has taken a different swing at the same antigen. In February 2026, IDEAYA announced that the first patient had been enrolled in its Phase 1 dose-escalation/expansion trial evaluating IDE034, a potential first-in-class PTK7/B7-H3 bispecific TOP1 antibody-drug conjugate [5]. The design rationale is unusually specific: IDEAYA estimates that B7-H3 and PTK7 are co-expressed in approximately 30–40% of certain large solid tumor types — including lung, breast, ovarian, and colorectal cancers — while exhibiting minimal dual-antigen expression in normal tissue [5]. The drug is designed to be internalized only when both antigens are co-expressed on the same tumor cell, an architecture intended to enhance selectivity and tolerability compared to monovalent antibody formats.
In its first-quarter 2026 update, IDEAYA reaffirmed plans to provide a clinical data update for IDE034 by year-end 2026 and confirmed that patient dosing in the trial had triggered a $5 million milestone payment to its collaboration partner Biocytogen [6].
Beyond Antibodies: A Radiopharmaceutical Approach
A third U.S.-listed program is testing whether B7-H3 can be hit with radiation rather than a payload-conjugated antibody. Radiopharm Theranostics Ltd. (NASDAQ: RADX), through its Radiopharm Ventures joint venture with The University of Texas MD Anderson Cancer Center, is advancing 177Lu-BetaBart (RV-01), a Lutetium-177-tagged engineered monoclonal antibody designed with strong affinity for the 4Ig isoform of B7-H3 — the first clinical trial globally to target B7-H3 with a systemic radiopharmaceutical [7]. Radiopharm dosed the first patient in the First-In-Human Phase 1/2a clinical trial of 177Lu-BetaBart on February 24, 2026 [8]. The trial follows FDA IND clearance received in July 2025, and in January 2026 Radiopharm announced it had increased its ownership stake in Radiopharm Ventures to 87.5%, deepening its exposure to the BetaBart program [7].
Taken together — antibody-drug conjugates, bispecific ADCs, systemic radiopharmaceuticals, natural killer cell engagers — B7-H3 is now being attacked from four distinct therapeutic angles across at least four publicly traded U.S. companies in 2026 alone.
Why Subcutaneous Matters in This Wave
Among that group, GT Biopharma's GTB-5550 stands out for two structural reasons. First, the engager is the only one of the named programs that relies on natural killer cells rather than T cells, antibody payloads, or radiation. NK cells are part of the innate immune system, act faster than T cells, do not require MHC presentation, and have historically been associated with lower rates of cytokine release syndrome — features that have made them a focus of an entire emerging therapeutic category. Second, GTB-5550 is being administered subcutaneously, in the abdominal area, for five consecutive days during Week 1 and Week 2 of each four-week cycle [2]. Subsequent cycles are dosed three times weekly for two weeks followed by two weeks of no treatment.
The implication for patients — and for the eventual commercial logistics of any approved therapy — is that treatment may not require an infusion center.
A Pipeline-Defining Year
GT Biopharma has indicated that it expects to provide updates on the GTB-5550 trial throughout the second half of 2026 as enrollment progresses through the dose-escalation cohorts [2]. Patients are followed for 12 months to determine progression-free survival and overall survival. The trial is registered under clinicaltrials.gov identifier NCT07541573 [2].
In a category that took two decades to get its first programs into the clinic, the pace of activity in 2026 alone is striking. From a small-cap NK cell engager developer to a mega-cap bispecific antibody company partnering with GSK, B7-H3 is no longer the target that pharma circled and walked away from. It is the target everyone is racing to crack — and the patient just dosed in San Francisco this week is one more data point in that race.
Management
Michael Breen
Executive Chairman, Board of Directors, Chief Executive Officer
Michael Breen is an English qualified solicitor/attorney and was formerly the Managing Director of the Sports and Entertainment Division of Bank Insinger de Beaufort N. V., which is a wealth management organization and was part of BNP Paribas Group, one of the world's largest banks. The holding company Insinger de Beaufort Holdings S.A. was listed on the Luxembourg Stock Exchange. Mr. Breen was also a director and major shareholder of an affiliate of Insinger de Beaufort Holdings S.A. Mr. Breen is a former senior equity partner in the 400+ partner and 50+ office law firm of Clyde & Co, whose head office is based in the City of London, England.
Jeffrey S. Miller, M.D.
Consulting Senior Medical Director
Jeffrey S. Miller, MD, received a Bachelor of Science degree from Northwestern University in Evanston, Illinois and received his MD from Northwestern University School of Medicine. He completed an internship and residency in Internal Medicine at the University of Iowa in Iowa City. After completing a post-doctoral fellowship in Hematology, Oncology and Transplantation at the University of Minnesota, he joined the faculty in 1991. Dr. Miller is currently a Professor of Medicine at the University of Minnesota. He is the Interim Director of the University of Minnesota Masonic Cancer Center. He has more than 20 years of experience studying the biology of NK cells and other immune effector cells and their use in clinical immunotherapy with over 170 peer-reviewed publications. He is a member of numerous societies such as the American Society of Hematology, the American Association of Immunologists, a member of the American Society of Clinical Investigation since 1999. He serves on the editorial board for Blood and is a reviewer for a number of journals and NIH grants.
Alan L. Urban
Chief Financial Officer
Alan Urban has over 30 years of corporate finance and accounting experience for a variety of public and private companies. Most notably Mr. Urban served as a member of the board of directors of GT Biopharma, Inc. (NASDAQ: GTBP), from mid-2022 to mid-2023; and as Chief Financial Officer for Research Solutions, Inc. (NASDAQ: RSSS), a SaaS and content provider in the scientific, technical and medical information space, for over a decade from 2011 to 2021. Earlier in his career, Mr. Urban served as Chief Financial Officer for ReachLocal, Inc. (formerly NASDAQ: RLOC), an internet marketing company; and as Vice President of Finance for Infotrieve, Inc., a content provider in the scientific, technical and medical information space. Mr. Urban has been a Certified Public Accountant (currently inactive) since 1998, and received a B.S. in Business, with a concentration in Accounting Theory and Practice, from California State University, Northridge.
NEWS
May 14, 1026
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
May 14, 1026
May 14, 1026
Replays from RedChip's Biotech Investor Conference Now Available
Apr 20, 2026
Apr 10, 2026
GT Biopharma to Participate in the 38th Annual Roth Conference
Mar 11, 2026
GT Biopharma Reports Full Year 2025 Financial Results
Mar 2, 2026
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
Feb 17, 2026
Feb 3, 2026
Jan 15, 2026
Sincerely,
